AU2002256803B2 - Pharmaceutical use for secreted bacterial effector proteins - Google Patents

Pharmaceutical use for secreted bacterial effector proteins Download PDF

Info

Publication number
AU2002256803B2
AU2002256803B2 AU2002256803A AU2002256803A AU2002256803B2 AU 2002256803 B2 AU2002256803 B2 AU 2002256803B2 AU 2002256803 A AU2002256803 A AU 2002256803A AU 2002256803 A AU2002256803 A AU 2002256803A AU 2002256803 B2 AU2002256803 B2 AU 2002256803B2
Authority
AU
Australia
Prior art keywords
leu
ser
ile
asn
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002256803A
Other languages
English (en)
Other versions
AU2002256803A1 (en
Inventor
Clifford Charles Shone
John Mark Sutton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Publication of AU2002256803A1 publication Critical patent/AU2002256803A1/en
Assigned to HEALTH PROTECTION AGENCY reassignment HEALTH PROTECTION AGENCY Amend patent request/document other than specification (104) Assignors: HEALTH PROTECTION AGENCY
Application granted granted Critical
Publication of AU2002256803B2 publication Critical patent/AU2002256803B2/en
Assigned to SYNTAXIN LIMITED reassignment SYNTAXIN LIMITED Request for Assignment Assignors: HEALTH PROTECTION AGENCY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002256803A 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins Ceased AU2002256803B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins
GB0112687.9 2001-05-24
PCT/GB2002/002384 WO2002096467A2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins

Publications (2)

Publication Number Publication Date
AU2002256803A1 AU2002256803A1 (en) 2003-05-08
AU2002256803B2 true AU2002256803B2 (en) 2006-11-09

Family

ID=9915236

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256803A Ceased AU2002256803B2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins

Country Status (8)

Country Link
US (1) US20040208889A1 (https=)
EP (1) EP1390400A2 (https=)
JP (2) JP2004533250A (https=)
CN (1) CN100439394C (https=)
AU (1) AU2002256803B2 (https=)
CA (1) CA2448963A1 (https=)
GB (1) GB0112687D0 (https=)
WO (1) WO2002096467A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
US20090092652A1 (en) * 2004-08-20 2009-04-09 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
AU2006233929B2 (en) * 2005-04-11 2012-05-31 Yeda Research And Development Co.Ltd. Chimeric proteins comprising Yersinia Yop, their preparation and pharmaceutical compositions containing them
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
JP5714692B2 (ja) * 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
WO2012054693A1 (en) * 2010-10-22 2012-04-26 Trudeau Institute Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
CN102807621B (zh) 2011-06-01 2016-04-13 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
CN108137654A (zh) * 2015-05-15 2018-06-08 内布拉斯加大学董事会 适用于将分子递送进入选定细胞的工程改造的肉毒梭菌毒素
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US20210054033A1 (en) * 2018-01-25 2021-02-25 The Wistar Institute Of Anatomy And Biology Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056817A1 (en) * 1997-06-09 1998-12-17 Karolinska Innovations Ab Composition and methods for the treatment of inflammatory diseases
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056817A1 (en) * 1997-06-09 1998-12-17 Karolinska Innovations Ab Composition and methods for the treatment of inflammatory diseases
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Also Published As

Publication number Publication date
WO2002096467A3 (en) 2003-04-10
JP2004533250A (ja) 2004-11-04
JP2009286794A (ja) 2009-12-10
CN100439394C (zh) 2008-12-03
CN1531549A (zh) 2004-09-22
US20040208889A1 (en) 2004-10-21
GB0112687D0 (en) 2001-07-18
WO2002096467A2 (en) 2002-12-05
CA2448963A1 (en) 2002-12-05
EP1390400A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
AU2002256803B2 (en) Pharmaceutical use for secreted bacterial effector proteins
KR102530925B1 (ko) 신규 보툴리눔 신경독소 및 그의 유도체
AU2006207726B2 (en) Recombinant expression of proteins in a disulfide-bridged, two-chain form
AU754883B2 (en) Delivery of superoxide dismutase to neuronal cells
AU2002256803A1 (en) Pharmaceutical use for secreted bacterial effector proteins
US20040071736A1 (en) Methods and compounds for the treatment of mucus hypersecretion
US20120128700A1 (en) Constructs for delivery of therapeutic agents to neuronal cells
CN101432296A (zh) 聚乙二醇化的突变的肉毒梭菌毒素
WO2018109447A1 (en) Neurotoxins
KR20150080615A (ko) 미분화 세포 제거 방법
US7368532B2 (en) Constructs for delivery of therapeutic agents to neuronal cells
EP1523336B1 (en) Targeted agents for nerve regeneration
CN108137654A (zh) 适用于将分子递送进入选定细胞的工程改造的肉毒梭菌毒素
Lorenzetti et al. Genetic grafting of membrane‐acting peptides to the cytotoxin dianthin augments its ability to de‐stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin‐toxin conjugates
Lin et al. Purification and characterization of a novel cell-penetrating carrier similar to cholera toxin chimeric protein
Jia et al. Highly efficient method for intracellular delivery of proteins mediated by cholera toxin-induced protein internalization
WO2022241167A1 (en) Delivery constructs derived from bacterial toxins and uses thereof
Liu et al. Design, preparation and characterization of octopus-like self-releasing intracellular protein transporter LEB5 based on Escherichia coli heat-labile enterotoxin
Pinheiro et al. Exploring protein–protein ligation approaches for the cytosolic delivery of antigens using AIP56
Piot et al. Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications. Toxins 2021, 13, 36
EP1800696A1 (en) MBP-mediated molecular cargo delivery into cells

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HEALTH PROTECTION AGENCY

Free format text: FORMER APPLICANT(S): HEALTH PROTECTION AGENCY

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SYNTAXIN LIMITED

Free format text: FORMER OWNER WAS: HEALTH PROTECTION AGENCY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired